Enhancing macrocyclic diterpenes as multidrug-resistance reversers: Structure-activity studies on jolkinol D derivatives

Journal of Medicinal Chemistry

Volumn 56, Issue 3, 2013, Pages 748-760

  Reis, Mariana ^a   Ferreira, Ricardo J ^a   Santos, Maria M M ^a   Dos Santos, Daniel J V A ^a   Molnár, Joseph ^b   Ferreira, Maria José U ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DITERPENE; DOXORUBICIN; JOLKINOATE A; JOLKINOATE B; JOLKINOATE C; JOLKINOATE D; JOLKINOATE E; JOLKINOATE F; JOLKINOATE G; JOLKINOATE I; JOLKINOATE J; JOLKINOATE K; JOLKINOATE L; JOLKINOATE M; JOLKINODIOL; JOLKINOL D; MULTIDRUG RESISTANCE PROTEIN 1; OCTANOL; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DERIVATIZATION; DRUG DESIGN; EUPHORBIA; EUPHORBIA PISCATORIA; HYDROLYSIS; IC 50; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARTITION COEFFICIENT; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA;

ANIMALS; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; DITERPENES; DRUG RESISTANCE, MULTIPLE; HUMANS; MACROCYCLIC COMPOUNDS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; P-GLYCOPROTEIN; SPECTROMETRY, FLUORESCENCE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84873898843     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301441w     Document Type: Article

References (41)

1. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2002, 2, 48-58
2. Baird, R. D.; Kaye, S. B. Drug resistance reversal-Are we getting closer? Eur. J. Cancer 2003, 39, 2450-2461
3. Sarkadi, B.; Homolya, L.; Szakacs, G.; Varadi, A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system Physiol. Rev. 2006, 86, 1179-1236
4. Sauna, Z. E.; Kim, I. W.; Ambudkar, S. V. Genomics and the mechanism of P-glycoprotein (ABCB1) J. Bioenerg. Biomembr. 2007, 39, 481-487
5. Ambudkar, S. V.; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P-glycoprotein: from genomics to mechanism Oncogene 2003, 22, 7468-7485
6. Ambudkar, S. V.; Dey, S.; Hrycyna, C. A.; Ramachandra, M.; Pastan, I.; Gottesman, M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 1999, 39, 361-398
7. Sauna, Z. E.; Ambudkar, S. V. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2515-2520
8. Ozben, T. Mechanisms and strategies to overcome multiple drug resistance in cancer FEBS Lett. 2006, 580, 2903-2909
9. Robert, J.; Jarry, C. Multidrug resistance reversal agents J. Med. Chem. 2003, 46, 4805-4817
10. Thomas, H.; Coley, H. M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer Control 2003, 10, 159-165
11. O'Connor, R. A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance Curr. Cancer Drug Targets 2009, 9, 273-280
12. Shukla, S.; Ohnuma, S.; Ambudkar, S. V. Improving cancer chemotherapy with modulators of ABC drug transporters Curr. Drug Targets 2011, 12, 621-630
13. Tsuruo, T, I. H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res. 1981, 41, 1967-1972
14. Slater, L. M.; Sweet, P.; Stupecky, M.; Gupta, S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro J. Clin. Invest. 1986, 77, 1405-1408
15. Warner, E.; Hedley, D.; Andrulis, I.; Myers, R.; Trudeau, M.; Warr, D.; Pritchard, K. I.; Blackstein, M.; Goss, P. E.; Franssen, E.; Roche, K.; Knight, S.; Webster, S.; Fraser, R. A.; Oldfield, S.; Hill, W.; Kates, R. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen Clin. Cancer Res. 1998, 4, 1451-1457
16. Boote, D. J.; Dennis, I. F.; Twentyman, P. R.; Osborne, R. J.; Laburte, C.; Hensel, S.; Smyth, J. F.; Brampton, M. H.; Bleehen, N. M. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer J. Clin. Oncol. 1996, 14, 610-618
17. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J. A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576 Cancer Res. 2001, 61, 749-758
18. Dantzig, A. H.; Shepard, R. L.; Cao, J.; Law, K. L.; Ehlhardt, W. J.; Baughman, T. M.; Bumol, T. F.; Starling, J. J. Reversal of P-glycoprotein- mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979 Cancer Res. 1996, 56, 4171-4179
19. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 2009, 323, 1718-1722
20. Klepsch, F.; Ecker, G. F. Impact of the recent mouse P-glycoprotein structure for structure-based ligand design Mol. Inf. 2010, 29, 276-286
21. Valente, C.; Ferreira, M. J.; Abreu, P. M.; Gyemant, N.; Ugocsai, K.; Hohmann, J.; Molnar, J. Pubescenes, jatrophane diterpenes, from Euphorbia pubescens, with multidrug resistance reversing activity on mouse lymphoma cells Planta Med. 2004, 70, 81-84
22. Madureira, A. M.; Ferreira, M. J. U.; Gyemant, N.; Ugocsai, K.; Ascenso, J. R.; Abreu, P. M.; Hohmann, J.; Molnar, J. Rearranged jatrophane-type diterpenes from Euphorbia species. Evaluation of their effects on the reversal of multidrug resistance Planta Med. 2004, 70, 45-49
23. Madureira, A. M.; Gyemant, N.; Ascenso, J. R.; Abreu, P. M.; Molnar, J.; Ferreira, M. J. U. Euphoportlandols A and B, tetracylic diterpene polyesters from Euphorbia portlandica and their anti-MDR effects in cancer cells J. Natl. Prod. 2006, 69, 950-953
24. Duarte, N.; Jardanhazy, A.; Molnar, J.; Hilgeroth, A.; Ferreira, M. J. U. Synergistic interaction between P-glycoprotein modulators and epirubicine on resistant cancer cells Bioorg. Med. Chem. 2008, 16, 9323-9330
25. Duarte, N.; Lage, H.; Ferreira, M. J. Three new jatrophane polyesters and antiproliferative constituents from Euphorbia tuckeyana Planta Med. 2008, 74, 61-68
26. Uemura, D.; Nakayama, Y.; Nobuhara, Y.; Katayama, T.; Hirata, Y. The structures of diterpenes isolated from Euphorbia Jolkini Boiss Tetrahedron Lett. 1977, 17, 4593-4596
27. Voigt, B.; Coburger, C.; Monar, J.; Hilgeroth, A. Structure-activity relationships of novel N -acyloxy-1,4-dihydropyridines as P-glycoprotein inhibitors Bioorg. Med. Chem. 2007, 15, 5110-5113
28. Overton, W. R. Modified histogram subtraction technique for analysis of flow cytometry data Cytometry 1988, 9, 619-626
29. Licht, T.; Fiebig, H. H.; Bross, K. J.; Herrmann, F.; Berger, D. P.; Shoemaker, R.; Mertelsmann, R. Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro Int. J. Cancer 1991, 49, 630-637
30. Didziapetris, R.; Japertas, P.; Avdeef, A.; Petrauskas, A. Classification analysis of P-glycoprotein substrate specificity J. Drug Targeting 2003, 11, 391-406
31. Ferreira, R. J.; Ferreira, M.-J. U.; dos Santos, D. J. V. A. Insights on P-glycoprotein's efflux mechanism obtained by molecular dynamics simulations J. Chem. Theory Comput. 2012, 8, 1853-1864
32. Ferreira, R. J.; dos Santos, D. J.; Ferreira, M. J.; Guedes, R. C. Toward a better pharmacophore description of P-glycoprotein modulators, based on macrocyclic diterpenes from Euphorbia species J. Chem. Inf. Model. 2011, 51, 1315-1324
33. Reis, M.; Ferreira, R. J.; Serly, J.; Duarte, N.; Madureira, A. M.; Santos, D. J.; Molnar, J.; Ferreira, M. J. Colon adenocarcinoma multidrug resistance reverted by Euphorbia diterpenes: structure-activity relationships and pharmacophore modeling Anti-Cancer Agents Med. Chem. 2012, 12, 1015-1024
34. Molecular Operating Environment (MOE), version 2010.10; Chemical Computing Group Inc. (1010 Sherbooke Street West, Suite No. 910, Montreal, Quebec, H3A 2R7, Canada), 2010.
35. Pastan, I.; Gottesman, M. M.; Ueda, K.; Lovelace, E.; Rutherford, A. V.; Willingham, M. C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4486-4490
36. CalcuSyn, version 2.00; BIOSOFT: Great Shelford, Cambridge, U.K.; http://www.biosoft.com.
37. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 2010, 70, 440-446
38. Motulsky, H.; Christopoulos, A. Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting; Oxford University Press: New York, 2004.
39. GraphPad Prism, version 5.00; GraphPad Software: San Diego, CA, U.S.; www.graphpad.com.
40. TANAGRA project, 1.4.41. http://chirouble.univ-lyon2.fr/∼ricco/ tanagra/en/tanagra.html.
41. Rakotomalala, R. TANAGRA: A Free Software for Research and Academic Purposes. Advances in Grid Computing, Proceedings of EGC 2005, European Grid Conference, Amsterdam, The Netherlands, Feb 14-16, 2005; Springer: Berlin, 2005; Vol. 2, pp 697-702, RNTI-E-3.